Text Size
15 studies found for:    Alzheimer rosiglitazone

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
2 Completed Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone Extended Release 2mg;   Drug: Rosiglitazone Extended Release 8mg;   Other: Placebo
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
3 Terminated Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
Conditions: Alzheimer's Disease;   Mild-to-moderate Alzheimer
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
4 Completed Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: rosiglitazone maleate
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
5 Completed Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: rosiglitazone
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
6 Terminated Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers
Conditions: Alzheimer's Disease;   Mild-to-moderate Alzheimers Disease
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
7 Completed Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone (Extended Release)
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
8 Terminated Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease
Condition: Alzheimer's Disease
Interventions: Drug: Rosiglitazone XR (extended release) oral tablets;   Drug: Placebo
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
9 Completed Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR (extended release) oral tablets
Sponsor: GlaxoSmithKline
Age Groups: Adult / Senior
10 Completed PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers
Condition: Alzheimer's Disease
Intervention: Drug: Rosiglitazone XR
Sponsor: GlaxoSmithKline
Age Group: Adult
11 Completed A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.
Condition: Alzheimer's Disease
Intervention: Drug: BRL-049653
Sponsor: GlaxoSmithKline
Age Group: Adult
12 Completed Insulin, Neurogenetics and Memory in Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: rosiglitazone
Sponsor: Department of Veterans Affairs
Age Groups: Adult / Senior
13 Active, not recruiting Rosiglitazone Effects on Cognition for Adults in Later Life
Condition: Mild Cognitive Impairment
Intervention: Drug: Rosiglitazone
Sponsor/Collaborators: University of Washington;   National Institute on Aging (NIA);   GlaxoSmithKline
Age Groups: Adult / Senior
14 Completed Drug Interaction Study Between AZD3480 and Cytochrome P450
Conditions: Metabolism;   Alzheimer's Disease
Interventions: Drug: AZD3480;   Drug: Placebo;   Drug: Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
Sponsor: AstraZeneca
Age Group: Adult
15 Withdrawn QTc Study of Rosi XR in Healthy Volunteers
Condition: Alzheimer's Disease
Interventions: Drug: Rosi XR;   Other: Placebo;   Drug: Moxifloxacin
Sponsor: GlaxoSmithKline
Age Group: Adult
To Top

† Indicates status has not been verified in more than two years